Literature DB >> 27855075

In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.

Ken B Waites1, Donna M Crabb2, Lynn B Duffy2, Jorgen S Jensen3, Yang Liu4, Susanne Paukner5.   

Abstract

Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains, and the results were compared with those of azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin testing. Lefamulin was highly active against all strains tested, with all MICs at ≤0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Mycoplasma pneumoniae; lefamulin; pleuromutilin; pneumonia; susceptibility testing

Mesh:

Substances:

Year:  2017        PMID: 27855075      PMCID: PMC5278710          DOI: 10.1128/AAC.02008-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs).

Authors:  Helio S Sader; Susanne Paukner; Zrinka Ivezic-Schoenfeld; Douglas J Biedenbach; Franz J Schmitz; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2012-01-27       Impact factor: 5.790

2.  Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.

Authors:  Ken B Waites; D M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

3.  Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia.

Authors:  F Cardinale; M Chironna; R Dumke; A Binetti; C Daleno; A Sallustio; A Valzano; S Esposito
Journal:  Eur Respir J       Date:  2011-06       Impact factor: 16.671

4.  Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010.

Authors:  Susanne Paukner; Helio S Sader; Zrinka Ivezic-Schoenfeld; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

5.  Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic.

Authors:  C Heilmann; L Jensen; J S Jensen; K Lundstrom; D Windsor; H Windsor; D Webster
Journal:  J Infect       Date:  2001-11       Impact factor: 6.072

Review 6.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.

Authors:  T S Lucier; K Heitzman; S K Liu; P C Hu
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

8.  Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012.

Authors:  Fei Zhao; Gang Liu; Jiang Wu; Bin Cao; Xiaoxia Tao; Lihua He; Fanliang Meng; Liang Zhu; Min Lv; Yudong Yin; Jianzhong Zhang
Journal:  Antimicrob Agents Chemother       Date:  2012-12-21       Impact factor: 5.191

9.  Macrolide-Resistant Mycoplasma pneumoniae, United States.

Authors:  Xiaotian Zheng; Stella Lee; Rangaraj Selvarangan; Xuan Qin; Yi-Wei Tang; Jeffrey Stiles; Tao Hong; Kathleen Todd; Amy E Ratliff; Donna M Crabb; Li Xiao; T Prescott Atkinson; Ken B Waites
Journal:  Emerg Infect Dis       Date:  2015-08       Impact factor: 6.883

View more
  21 in total

Review 1.  Mycoplasma pneumoniae from the Respiratory Tract and Beyond.

Authors:  Ken B Waites; Li Xiao; Yang Liu; Mitchell F Balish; T Prescott Atkinson
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

2.  Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016).

Authors:  Susanne Paukner; Steven P Gelone; S J Ryan Arends; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

3.  Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms.

Authors:  Rodrigo E Mendes; Susanne Paukner; Timothy B Doyle; Steven P Gelone; Robert K Flamm; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

4.  In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens.

Authors:  Susanne Paukner; Astrid Gruss; Jørgen Skov Jensen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

5.  In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Li Xiao; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

Review 6.  New Horizons in Mycoplasma genitalium Treatment.

Authors:  Catriona S Bradshaw; Jorgen S Jensen; Ken B Waites
Journal:  J Infect Dis       Date:  2017-07-15       Impact factor: 5.226

Review 7.  Refractory Mycoplasma pneumoniae Pneumonia in Children: Early Recognition and Management.

Authors:  Lin Tong; Shumin Huang; Chen Zheng; Yuanyuan Zhang; Zhimin Chen
Journal:  J Clin Med       Date:  2022-05-17       Impact factor: 4.964

8.  In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms.

Authors:  G Xue; D M Crabb; L Xiao; Y Liu; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

9.  Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities.

Authors:  Thomas M File; Elizabeth Alexander; Lisa Goldberg; Anita F Das; Christian Sandrock; Susanne Paukner; Gregory J Moran
Journal:  BMC Pulm Med       Date:  2021-05-08       Impact factor: 3.317

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.

Authors:  Matthew William McCarthy
Journal:  Clin Pharmacokinet       Date:  2021-07-13       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.